The document “Application for quotation of +securities” was lodged with ASX on 6th January, 2022.
Please click to review the full announcement at ASX.
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance
Highlights: Imagion presented results from MagSense® HER2 Phase I study at global breast cancer meeting showing safety and detectability Tasks expert panel of radiologists with
Imaging agent aids in resolving nodal status MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of
We’re on a mission to make cancer more detectable.